Therefore, overexpression of TRIM28 or downregulation of TRIM17 reduce the protein level of BCL2A1 and restore sensitivity to B-Raf proto-oncogene, serine/threonine kinase (BRAF)-targeted therapy in melanoma cells that exhibit a survival dependency on BCL2A1 [71]. This evidence concerns the gene BCL2A1 and melanoma.